Please use this identifier to cite or link to this item: 10.3390/biomedicines9070814
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDubnika, Arita-
dc.contributor.authorEgle, Karina-
dc.contributor.authorSkrinda-Melne, Marite-
dc.contributor.authorSkadins, Ingus-
dc.contributor.authorRajadas, Jayakumar-
dc.contributor.authorSalma, Ilze-
dc.date.accessioned2021-09-01T07:50:01Z-
dc.date.available2021-09-01T07:50:01Z-
dc.date.issued2021-07-13-
dc.identifier.citationDubnika , A , Egle , K , Skrinda-Melne , M , Skadins , I , Rajadas , J & Salma , I 2021 , ' Development of vancomycin delivery systems based on autologous 3d platelet-rich fibrin matrices for bone tissue engineering ' , Biomedicines , vol. 9 , no. 7 , 814 . https://doi.org/10.3390/biomedicines9070814-
dc.identifier.issn2227-9059-
dc.identifier.otherunpaywall: 10.3390/biomedicines9070814-
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/6145-
dc.descriptionFunding Information: Funding: This research was funded by the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 857287 and the Latvian Council of Science research project No. lzp-2020/1-0054 “Development of antibacterial autologous fibrin matrices in maxillofacial surgery (MATRI-X)”. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.-
dc.description.abstractAutologous platelet-rich fibrin (PRF) is derived from the blood and its use in the bone tissue engineering has emerged as an effective strategy for novel drug and growth factor delivery systems. Studies have approved that combined therapy with PRF ensures higher biological outcomes, but patients still undergo additional treatment with antibiotic drugs before, during, and even after the implantation of biomaterials with PRF. These systematically used drugs spread throughout the blood and lead not only to positive effects but may also induce adverse side effects on healthy tissues. Vancomycin hydrochloride (VANKA) is used to treat severe Staphylococcal infections but its absorption in the target tissue after oral administration is low; therefore, in this study, we have developed and analyzed two kinds of VANKA carriers—liposomes and microparticles in 3D PRF matrices. The adjustment, characterization, and analysis of VANKA carriers in 3D PRF scaffolds is carried out in terms of encapsulation efficiency, drug release kinetics and antibacterial activity; furthermore, we have studied the micro-and macrostructure of the scaffolds with microtomography.en
dc.format.extent19-
dc.format.extent7092566-
dc.language.isoeng-
dc.relation.ispartofBiomedicines-
dc.rightsinfo:eu-repo/semantics/openAccess-
dc.subjectDrug delivery-
dc.subjectDrug release-
dc.subjectLiposomes-
dc.subjectMicrocapsules-
dc.subjectMicrotomography-
dc.subjectPhospholipids-
dc.subjectPlatelet-rich fibrin-
dc.subjectPLGA-
dc.subjectVancomycin-
dc.subject3.1 Basic medicine-
dc.subject2.6 Medical engineering-
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database-
dc.subjectMedicine (miscellaneous)-
dc.subjectGeneral Biochemistry,Genetics and Molecular Biology-
dc.titleDevelopment of vancomycin delivery systems based on autologous 3d platelet-rich fibrin matrices for bone tissue engineeringen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article-
dc.identifier.doi10.3390/biomedicines9070814-
dc.contributor.institutionDepartment of Biology and Microbiology-
dc.contributor.institutionRīga Stradiņš University-
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85111167131&partnerID=8YFLogxK-
dc.description.statusPeer reviewed-
Appears in Collections:Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure

Files in This Item:


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.